Publicacións en colaboración con investigadores/as de Dana–Farber Cancer Institute (3)

2023

  1. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer

    Expert Review of Anticancer Therapy, Vol. 23, Núm. 1, pp. 95-106

  2. Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort

    Journal of Clinical Medicine, Vol. 12, Núm. 1

2021

  1. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients with EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial

    JAMA Oncology, Vol. 7, Núm. 12, pp. 1772-1781